Definitive Radiotherapy/Chemoradiotherapy Results in Geriatric Non-Small Cell Lung Cancer Patients with Multiple Comorbidity

Year 2024, Volume: 3 Issue: 4, 152 - 160, 27.12.2024

Yasin Caygın , İpek Pınar Aral , Gonca Altınışık İnan , Muhammed Yılmaz Çağkan Ergiden , Yılmaz Tezcan

Abstract

INTRODUCTION: It was aimed to evaluate the definitive radiotherapy (RT)/chemoradiotherapy outcomes in geriatric non-small cell lung cancer (NSCLC) patients with multiple comorbidities.

METHODS: Patients who received RT 06.03.2019 and 24.10.2022 in XXX Hospital were analyzed retrospectively. The primary endpoints were RT interruption, acute adverse events (AAE), complete of treatment. The secondary endpoints were overall survival (OS), disease-free survival (DFS).

RESULTS: The results of 62 patients who received definitive RT/CRT were analyzed. Median follow-up time was 16 (2-55) months. The median age of the patients was 75(70-89) years. The median number of comorbidities was 3(2-6). Thirty-seven (59.7%) patients received concurrent chemotherapy (CRT);12(19.4%) patients received induction chemotherapy. One patient (1.6%) could not complete the RT and RT was interrupted in 6 (9.7%) patients. RT interruption was more common in patients with cerebrovascular disease (CVD) (p=0.002; OR5.5; CI %954,3-7). AAE were noted in 20 (32.3%) patients and AAEs increased with CRT (p=0.006; OR 6.2;95%CI1.5-24.4). Eighteen (29%) patients relapsed, 11(17.7%) of relapses were locoregional while 7 (11.3%) were distant. Median DFS was 12 (range1-50) months. Significantly higher DFS was observed in patients with squamous cell cancer (SCC) (p=0.021; HR 2.8;95%CI1.12-7.18). Thirty-three (53.2%) patients have died. Twenty-seven (81.8%) patients died without relapse, 6(17.2%) died after relapse. Median OS was 14 (2-50) months. Patients who interrupted RT had lower OS (p=0.003; HR5.96;95%CI2.23-15.9). Patients with 3≥ comorbidities had lower OS (14 vs10 months) (p=0.053; HR2.3;CI95%0.98-5.8).

DISCUSSION AND CONCLUSION: Definitive RT/CRT is an effective treatment with acceptable toxicity in geriatric NSCLC patients with multiple comorbidities.

Keywords

Non-Small Cell Lung Cancer, Geriatric, Definitive Radiotherapy, Comorbidity

References

• 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249.
• 2. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–65.
• 3. Sarı M, Vatansever S. Current Trends in the Incidence of Non-small Cell Lung Cancer in Turkey: Lung Cancer Aging. EJMI. 2020;4(2):169–172.
• 4. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(5):497-530.
• 5. Zaborowska-Szmit M, Olszyna-Serementa M, Kowalski DM, Szmit S, Krzakowski M. Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy. Cancers (Basel). 2021; 13(18):4534.
• 6. Pentheroudakis G, ESMO Guidelines Committee. Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2020;31:1265–1266.
• 7. Watanabe K, Katsui K, Sugiyama S, et al. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. Radiat Oncol. 2021;16:39.
• 8. Parisi S, Lillo S, Cacciola A, et al. Non-stereotactic radiotherapy in older cancer patients. Heliyon. 2022;8(6):e09593.
• 9. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemiotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–2190.
• 10. Blanco R, Maestu I, de la Torre MG, Cassinello A, Nuñez I. A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol. 2015;26(3):451-463.
• 11. Gül ŞB, Mayadağlı A, Gümüş M. Treatment Approach for Lung Cancer of Geriatric Patients.J Kartal TR. 2014;25(3):257-260.
• 12. Roeder F, Jensen AD, Lindel K, Mattke M, Wolf F, Gerum S. Geriatric Radiation Oncology: What We Know and What Can We Do Better? Clin Interv Aging. 2023;18:689-711.
• 13. Antonio M, Saldaña J, Linares J, et al. Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer. Br J Cancer. 2018;118(5):639-647.
• 14. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630-637.
• 15. Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448-1457.
• 16. Brooks ED, Sun B, Zhao L, et al. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017;98(4):900-907.
• 17. Sigel K, Lurslurchachai L, et al. Effectiveness of radiation therapy alone for elderly patients with unresected stage III non-small cell lung cancer. Lung Cancer. 2013;82(2):266-270.
• 18. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103(6):792-802.
• 19. Cardia J, Calçada C, Pereira H. Treatment of lung cancer in the elderly: Influence of comorbidity on toxicity and survival. Rep Pract Oncol Radiother 2011;16(2):45-48.
• 20. Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004;59(7):602-627.
• 21. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002 ;54(2):357-364.
• 22. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63(3):667-671.
• 23. González Ferreira JA, Jaén Olasolo J, Azinovic I, Jeremic B. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother. 2015;20(5):328-39.
• 24. Mehta S, Ramey SJ, Kwon D, et al. Impact of radiotherapy duration on overall survival in squamous cell carcinoma of the anus. J Gastrointest Oncol 2020; 11(2):277-290. (DOI: 10.21037/jgo.2020.02.09)
• 25. Vitzthum L, Yuan J, Jones D, Boldt A, Dusenbery K. Reducing prolonged chemoradiation treatment times for cervical cancer. BMJ Open Qual. 2019 ;8(3):e000516.
• 26. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63(3):667-671.
• 27. Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1996;34(2):315-322.
• 28. Chen M, Jiang GL, Fu XL, et al. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer. Lung Cancer. 2000;28(1):11-19.
• 29. Jeremic B, Shibamoto Y, Milicic B, et al. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. Lung Cancer. 2003;40(3):317-23.
• 30. McMillan MT, Ojerholm E, Verma V, et al. Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017;98(5):1142-1152.
• 31. Zaki M, Dominello M, Dyson G, et al. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18:21-26.
• 32. Sakin A, Sahin S, Atci MM, et al. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology. 2021;27(1):26-34.
• 33. Miller ED, Fisher JL, Haglund KE, et al. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13:426-435.
• 34. Atagi S, Kawahara M, Tamura T,et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol. 2005;35(4):195-201.
• 35. Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13(7):671-678.
• 36. Atagi S, Mizusawa J, Ishikura S, et al. Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). Clin Lung Cancer. 2018;19(5):619-627.
• 37. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3(12):1468-1481.
• 38. Carmichael J, Degraff WG, Gamson J, Russo D, Gazdar AF, Levitt ML, Minna JD, Mitchell JB. Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol. 1989;25(3):527-534.
• 39. Nomori H, Shiraishi A, Honma K, et al. Differences between lung adenocarcinoma and squamous cell carcinoma in histological distribution of residual tumor after induction chemoradiotherapy. Discov Oncol. 2021;12(1):36.